Literature DB >> 30705112

Antithymocyte globulin and cyclosporin: standard of care also for older patients with aplastic anemia.

Andrea Bacigalupo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30705112      PMCID： PMC6355485          DOI： 10.3324/haematol.2018.207167

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.

Authors:  Danielle M Townsley; Phillip Scheinberg; Thomas Winkler; Ronan Desmond; Bogdan Dumitriu; Olga Rios; Barbara Weinstein; Janet Valdez; Jennifer Lotter; Xingmin Feng; Marie Desierto; Harshraj Leuva; Margaret Bevans; Colin Wu; Andre Larochelle; Katherine R Calvo; Cynthia E Dunbar; Neal S Young
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

2.  Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party.

Authors:  J Marsh; H Schrezenmeier; P Marin; O Ilhan; P Ljungman; S McCann; G Socie; A Tichelli; J Passweg; J Hows; A Raghavachar; A Locasciulli; A Bacigalupo
Journal:  Blood       Date:  1999-04-01       Impact factor: 22.113

3.  Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?

Authors:  Sabrina Giammarco; Régis Peffault de Latour; Simona Sica; Carlo Dufour; Gerard Socie; Jakob Passweg; Nicolaus Kröger; Eefke Petersen; Maria Teresa Van Lint; Rosi Oneto; Alessio Signori; Andrea Bacigalupo
Journal:  Blood       Date:  2018-03-16       Impact factor: 22.113

4.  A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  André Tichelli; Hubert Schrezenmeier; Gérard Socié; Judith Marsh; Andrea Bacigalupo; Ulrich Dührsen; Anke Franzke; Michael Hallek; Eckhard Thiel; Martin Wilhelm; Britta Höchsmann; Alain Barrois; Kim Champion; Jakob R Passweg
Journal:  Blood       Date:  2011-01-13       Impact factor: 22.113

5.  Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

Authors:  Paolo Anderlini; Juan Wu; Iris Gersten; Marian Ewell; Jakob Tolar; Joseph H Antin; Roberta Adams; Sally Arai; Gretchen Eames; Mitchell E Horwitz; John McCarty; Ryotaro Nakamura; Michael A Pulsipher; Scott Rowley; Eric Leifer; Shelly L Carter; Nancy L DiFronzo; Mary M Horowitz; Dennis Confer; H Joachim Deeg; Mary Eapen
Journal:  Lancet Haematol       Date:  2015-09-02       Impact factor: 18.959

6.  Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Monzr M Al Malki; Nitya Nathwani; Dongyun Yang; Saro Armenian; Sanjeet Dadwal; Jaroslava Salman; Sally Mokhtari; Thai Cao; Karamjeet Sandhu; Michelle Rouse; Matthew Mei; Haris Ali; Pablo Parker; Joseph Alvarnas; Eileen Smith; Margaret O Donnell; Guido Marcucci; David Snyder; Auayporn Nademanee; Stephen J Forman; Anthony Stein; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-09       Impact factor: 5.742

7.  Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia.

Authors:  Régis Peffault de Latour; Reza Tabrizi; Ambroise Marcais; Thierry Leblanc; Thierry Lamy; Mohamad Mohty; Suzanne Tavitian; Charlotte Jubert; Marlène Pasquet; Claire Galambrun; Stéphanie Nguyen; Jean Yves Cahn; Thorsten Braun; Eric Deconinck; Jacques Olivier Bay; Flore Sicre de Fontbrune; Fiorenza Barraco; Gérard Socié
Journal:  Am J Hematol       Date:  2018-02-14       Impact factor: 10.047

8.  Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning.

Authors:  S H Shin; Y W Jeon; J H Yoon; S A Yahng; S E Lee; B S Cho; K S Eom; Y J Kim; S Lee; C K Min; H J Kim; S G Cho; D W Kim; W S Min; J W Lee
Journal:  Bone Marrow Transplant       Date:  2016-06-27       Impact factor: 5.483

9.  Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia.

Authors:  Adrien Contejean; Matthieu Resche-Rigon; Jérôme Tamburini; Marion Alcantara; Fabrice Jardin; Etienne Lengliné; Lionel Adès; Didier Bouscary; Ambroise Marçais; Delphine Lebon; Cécile Chabrot; Louis Terriou; Fiorenza Barraco; Anne Banos; Lucile Bussot; Jean-Yves Cahn; Pierre Hirsch; Natacha Maillard; Laurence Simon; Luc-Matthieu Fornecker; Gerard Socié; Regis Peffault de Latour; Flore Sicre de Fontbrune
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

10.  First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012.

Authors:  Andrea Bacigalupo; Rosi Oneto; Hubert Schrezenmeier; Britta Hochsmann; Carlo Dufour; Seiji Kojima; Xiaofan Zhu; Xiaojuan Chen; Surapol Issaragrisil; Suporn Chuncharunee; Dae Chul Jeong; Sabrina Giammarco; Maria Teresa Van Lint; Yizhou Zheng; Carlos Vallejo
Journal:  Am J Hematol       Date:  2018-03-23       Impact factor: 10.047
  10 in total
  4 in total

1.  [Progress in diagnosis and treatment in the elderly patients with aplastic anemia].

Authors:  W W Qi; R Fu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

2.  Medication Regularity of Traditional Chinese Medicine in the Treatment of Aplastic Anemia Based on Data Mining.

Authors:  Nanxi Dong; Xujie Zhang; Dijiong Wu; Zhiping Hu; Wenbin Liu; Shu Deng; Baodong Ye
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-25       Impact factor: 2.650

3.  Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation.

Authors:  André Tichelli; Régis Peffault de Latour; Jakob Passweg; Cora Knol-Bout; Gérard Socié; Judith Marsh; Hubert Schrezenmeier; Britta Höchsmann; Andrea Bacigalupo; Sujith Samarasinghe; Alicia Rovó; Austin Kulasekararaj; Alexander Röth; Dirk-Jan Eikema; Paul Bosman; Peter Bader; Antonio Risitano; Carlo Dufour
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

4.  [Prediction and treatment prospect of immunosuppressive therapy in patients with severe aplastic anemia].

Authors:  J S Jia
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.